Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
NCT04897802 on ClinicalTrials.gov · last registry update 2026-01-20
Finished 30 April 2024, after enrolling 42 people. Primary outcome, as filed: Change in oxytocin concentration (pg/mL).
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Sponsor type
- Other
- Enrollment
- 42
- Started
- 2021-09-13
- Primary completion
- 2024-04-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in oxytocin concentration (pg/mL)
Conditions studied
Hypopituitarism · Central Diabetes Insipidus · Panhypopituitarism · Psychological Disorder · Social Isolation · Hypothalamic Diseases · Pituitary Diseases · Oxytocin Deficiency
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.